Italia markets open in 32 minutes

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,3000-0,0300 (-1,29%)
Alla chiusura: 04:00PM EDT
2,3700 +0,07 (+3,04%)
Dopo ore: 05:59PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,3300
Aperto2,3300
Denaro2,2000 x 1100
Lettera2,3700 x 800
Min-Max giorno2,2700 - 2,3300
Intervallo di 52 settimane2,1500 - 10,5800
Volume28.386
Media Volume115.793
Capitalizzazione48,948M
Beta (5 anni mensile)0,20
Rapporto PE (ttm)N/D
EPS (ttm)-1,8930
Prossima data utili10 ago 2022 - 15 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A28,80
  • GlobeNewswire

    Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

    DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct offering priced at-the-market under Nasdaq rules with an institutional investor of an aggregate of (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompanying

  • GlobeNewswire

    Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

    DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules, (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompa

  • GlobeNewswire

    Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology

    – Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum – – Currently no FDA-approved prescription therapies for the treatment of molluscum – – Novan advancing berdazimer gel, 10.3% toward New Drug Application (NDA) submission for molluscum contagiosum, targeted before end of 2022 DURHAM, N.C., May 19, 2022